Cystic Fibrosis Therapeutics Market Analysis
The Cystic Fibrosis Therapeutics Market is projected to reach US$ 15.42 billion by 2032, up from US$ 7.07 billion in 2023, with a CAGR of 9.04% from 2024 to 2032.
Cystic Fibrosis, a well-known genetic disease, is caused by mutations within the CFTR gene, affecting the lungs and digestive system. This disease interferes with the function of the CFTR ion channel, which plays a crucial role in regulating the flow across the cell membrane. The CFTR gene is located on chromosome 7, and this condition has a global impact, affecting various organ systems worldwide. In the United States alone, there are over 30,000 individuals affected, with a worldwide incidence exceeding 70,000.
Request a free sample copy of the report: https://www.renub.com/cystic-fibrosis-therapeutics-market-p.php
The symptoms of cystic fibrosis can include persistent coughing, wheezing, shortness of breath, digestive issues, and poor growth. However, with the approp